Infliximab is a chimeric monoclonal antibody that counters tumor necrosis factor alpha (TNFα) and is approved by the US Food and Drug Administration (FDA) as treatment for autoimmune diseases such as inflammatory bowel disease (Crohn's disease and ulcerative colitis), psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis [7]. The gene discussed is TNF; the disease is Crohn disease.